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Background: Monoclonal antibodies are a major class of biological therapies in human medicine but have not yet
been successfully applied to veterinary species. We have developed a novel approach, PETisation, to rapidly convert
antibodies for use in veterinary species. As an example, anti-nerve growth factor (anti-NGF) monoclonal antibodies
(mAbs) which are effective in reducing acute and chronic pain in rodents and man are potentially useful for treating
pain in dogs but a fully caninised mAb is required in order to avoid an immune response. The aim of this study
was to determine the optimal properties of a caninised anti-NGF mAb for safe, repeated administration to dogs, to
determine its pharmacokinetic properties and to evaluate its efficacy in a model of inflammatory pain in vivo.
Results: Starting with a rat anti-NGF mAb, we used a novel algorithm based on expressed canine immunoglobulin
sequences to design and characterise recombinant caninised anti-NGF mAbs. Construction with only 2 of the 4
canine IgG heavy chain isotypes (A and D) resulted in stable antibodies which bound and inhibited NGF with
high-affinity and potency but did not bind complement C1q or the high-affinity Fc receptor gamma R1 (CD64).
One of the mAbs (NV-01) was selected for scale-up manufacture, purification and pre-clinical evaluation. When
administered to dogs, NV-01 was well tolerated, had a long serum half-life of 9 days, was not overtly immunogenic
following repeated dosing in the dog and reduced signs of lameness in a kaolin model of inflammatory pain.
Conclusions: The combination of stability, high affinity and potency, no effector activity and long half-life, combined
with safety and activity in the model of inflammatory pain in vivo suggests that further development of the caninised
anti-NGF mAb NV-01 as a therapeutic agent for the treatment of chronic pain in dogs is warranted.
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Veterinary bio-therapeuticBackground
Current therapeutic options for pain management in
dogs are limited to a few classes of drugs including
non-steroidal anti-inflammatory drugs (NSAID), narcotics
and polysulphated glycosaminoglycans (PSGAG) [1,2].
Alternative therapeutic options are desirable, in par-
ticular for the management of chronic pain. Recently, a
new class of antibody drugs have been developed which
provide effective analgesia in rodents and man through
interference of binding of NGF to its cellular receptors
on nociceptive neurons.* Correspondence: dave.gearing@nexvet.com
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reproduction in any medium, provided the orWhereas during mammalian development, NGF is
essential for the survival of sensory and sympathetic
neurons [3,4] in the adult it is expressed locally at sites
of injury and inflammation and is a major factor pro-
moting pain and hyperalgesia [5,6]. NGF is produced
by a variety of inflammatory and immune cells, joint
chondrocytes and has also been detected in nerve and
neuroma preparations [5–7]. Following binding to its
receptor trkA on nociceptors, NGF causes immediate
and long-termexcitability through activation of ion
channels, the transient receptor potential vanilloid
receptor (TRPV1) and secondary neurotransmitters
including substance P and brain-derived neurotrophic
factor (BDNF) [5–7]. NGF also causes the sprouting of
nerve endings into the site of inflammation but does
not appear to play a role in inflammation per se [8].
Furthermore, mutations in NGF and its trkA receptorl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Neutralising antibodies to NGF are highly effective
analgesics in rodent models of inflammatory pain,
arthritis pain, cancer pain, and bone fracture pain
[5–7]. This encouraging biological activity has resulted
in the development of several NGF antagonists for the
treatment of pain in man.
The clinical efficacy of anti-human NGF mAbs has
been demonstrated in several human studies including
several large-scale phase 3 clinical trials: responses to
the pain associated with osteoarthritis (OA), lower back
pain and cystitis have been evaluated [5–7,9–12]. The
anti-NGF antibodies were generally very well tolerated
(consistent with a benign profile in 6-month primate
studies [13]), with mild to moderate, transient peripheral
sensation changes as the only consequences [7]. A small
number (16 of 6,800) of patients with OA that were
treated with anti-NGF mAbs required joint replacement
earlier than would be normally expected [14] and this
was attributed to “rapidly progressing osteoarthritis”. The
cause of this worsening has been debated, although in
some patients, the accelerated osteoarthritis was possibly
due to concomitant NSAID use [15].
Canine NGF and its receptor are closely homologous
to those of other species. NGF and trkA are expressed
in similar tissues in dog and man, appear to be under
similar control mechanisms, and have similar functions
[16–19]. NGF levels are significantly elevated in the synovial
fluid of osteoarthritic dogs with chronic lameness [20].
As with other mammals, the canine immune system
shares major immunoglobulin types, including IgG (of
which there are four isotypes: [21]) and IgG-Fc receptors
including the high-affinity FcR CD64 [NCBI reference:
NP_001002976.1, XP_003640260.1, XP_536141.3] [22]
and the neonatal FcRn [XP_533618.2, XP_003640095.1],
which potentiates IgG half-life in vivo [23,24].
Based on the conservation of the NGF system between
dog and man, it was at least possible that the rat anti-
human NGF MAb may also be reactive with canine
NGF. Furthermore, if this reactivity was of high affinity
which could be retained during the process of conversion
to a fully caninised antibody, we postulated that the
resulting antibody could well be an effective treatment
for pain in the dog. We therefore converted a high-affinity,
potent rat anti-NGF monoclonal antibody (αD11; [25])
to a fully canine form (NV-01) with no loss of bioactivity
by a novel process we term "PETisation". Unlike other
approaches for converting antibody sequences from
one species for use in another, such as CDR grafting,
which rely on germline sequences to provide recipient
V domain framework structures, the PETisation approach
makes use of sequences from expressed and circulating
IgG. This increases the likelihood that the resulting
antibody will be both active and recognized as self bythe recipient species, thereby overcoming immunogenicity
concerns.
The design, preparation and in vitro characteristics of
NV-01, together with preliminary studies investigating
its safety and effectiveness are described herein. Collect-
ively they show that NV-01 is a potent inhibitor of NGF,
is well tolerated and non-immunogenic and shows
promise as an analgesic in dogs. These preliminary data
support our hypothesis that NV-01 might be useful as a
treatment for pain in dogs (e.g. treatment of joint pain
associated with osteoarthritis, cancer pain and post-surgical
pain) and suggest that its further development as a vet-
erinary medicine is warranted.
Methods
Sources of NGF
A cDNA sequence encoding the amino acid sequence of
canine pre-pro beta NGF (Figure 1A) with a C-terminal
poly-His tag was synthesized from oligonucleotides, cloned
into pcDNA3.1+ expression vector and transiently trans-
fected into HEK293 cells at Geneart AG (Life Tech-
nologies, Regensberg, Germany). The supernatant was
harvested and purified by Ni-HiTrap chromatography
(GE Healthcare, Upsalla, Sweden). Purified mouse NGF
(muNGF) was purchased from Biosensis (Thebarton,
Australia).
Conversion of αD11 variable domains for use in the dog
In order to reduce the immunogenic potential of rat
αD11 [25] in the dog, changes were made to the heavy
and light chain variable domain framework sequences by
alignment with a matrix of predicted protein sequences
encoded by expressed canine IgG cDNA sequences.
Where the αD11 sequence corresponded to the matrix,
no changes were made. Where they differed, the most
similar amino acid (by charge, size, polarity) in the matrix
was substituted. If no similar amino acid was available,
the most abundant canine residue was chosen. The
changes made are illustrated in Figure 1B and 1C.
Twenty-two substitutions were made to the heavy
chain variable domain, of which 10 were conservative
and 17 substitutions were made to the light chain variable
domain, of which 9 were conservative. By this process,
termed PETisation, the αD11 framework sequences
were completely caninised, with minimal changes made
from the donor αD11 antibody.
Construction of NV-01 antibody heavy and light chains
The caninised αD11 heavy chain variable domain sequence
(caN) was combined with the αD11 heavy chain signal
sequence and the constant domain sequences of each
of the four canine IgG heavy chain isotypes A,B, C and
D [21] to form caN-HCA, caN-HCB, caN-HCC and
caN-HCD sequences, respectively. The caninised NV-01
Figure 1 NGF and anti-NGF antibody sequences. A) Alignment of the mature peptide sequence of NGF from human, mouse & dog. Identical
amino acids are indicated by dots and similar amino acids are underlined. B) Variable heavy & C) variable light chain sequences of the anti-NGF
antibody αD11 aligned to the caninised antibody NV-01. Identical amino acids are indicated by dots and similar amino acids are underlined.
Complementarity-determining regions (CDR) are boxed.
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with the αD11 light chain signal sequence and the constant
domain sequence of the canine kappa light chain to
form the caN-kLC sequence. The resulting amino acid
sequences were converted to codon-optimized nucleotide
sequences for expression in CHO cells (Geneart AG,
Life Technologies, Regensberg, Germany) and these cDNA
were cloned separately into pcDNA 3.1 + .
Co-expression in CHO cells by transient transfection
of caN-kLC light chain cDNA with each of the four
NV-01 heavy chain isotype cDNAs, caN-HCA, caN-HCB,
caN-HCC and caN-HCD, produced supernatants con-
taining antibodies “caN-HCA1 + kLC1”, “caN-HCB2 +kLC1”, “caN-HCC1 + kLC1” and “caN-HCD2 + kLC1”,
respectively.
Further modification of the heavy chain framework
sequence based on alignment to a larger number of canine
cDNA sequences resulted in the modified heavy chain
sequence “caN2-HCA1” (Figure 1). Co-expression of this
sequence with light chain caN-kLC1 formed the antibody
“caN2-HCA1-kLC1”, which was assigned the compound
number NV-01.
Recombinant antibody preparations
For small scale, antibodies were transiently expressed in
CHO cells (Geneart AG, Life Technologies, Regensberg,
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kLC1) was purified on protein A from CHO cell
supernatant. The type C anti-NGF antibody (caN-
HCC1 + kLC1) was purified on Protein G from CHO
cell supernatants. Type A & type D anti-NGF anti-
bodies (caN-HCA1 + kLC1 and ca-HCD2 + kLC1) could
not be purified using Protein A or G and were purified
using Protein L.
For in vivo experiments, NV-01 antibody was expressed
in CHO cells (Lonza Biologics plc, Cambridge, UK).
Stable pooled transfections of CHO cells with cDNA
encoding NV-01 heavy & light chains were cultured in
a fed batch system for 13 days, before harvesting of
supernatant containing NV-01. Clarified supernatant
was diluted 1:2 with 50 mM Tris pH 8.0. The protein
was captured on a HiTrap 5 ml anion exchange Q FF
column (GE Healthcare) and impurities removed by
washing the column with 50 mM Tris, 100 mM NaCl,
pH 8.0. The protein was eluted with 50 mM Tris,
200 mM NaCl, pH 8.0.
Anion exchange fractions containing antibody were
concentrated and diluted 1:10 with 50 mM sodium
phosphate, 1 M ammonium sulphate, pH 7.0. The protein
was captured on a HiTrap hydrophobic interaction Phenyl
HP column (GE Healthcare) and impurities removed by
washing the column with 50 mM sodium phosphate,
1 M ammonium sulphate, pH 7.0 (loading buffer). The
protein was eluted with a linear gradient from loading
buffer to 50 mM sodium phosphate, pH 7.0.
Material from the hydrophobic interaction step was
further purified by size exclusion chromatography
(HiLoad Superdex 200 pg 16/60, GE Healthcare), then
concentrated and formulated into phosphate buffered
saline (PBS) pH 7.3 by ultrafiltration (Amicon Ultra-15,
molecular weight cut-off 30,000; Millipore, Billerica,
USA).
NV-01 produced by this method was determined to
be >95% pure and 100% monomeric by size exclusion
HPLC. The preparations were free of detectable en-
dotoxin (<0.1 EU/mL; EndosafeW-PTS™ Charles River
Laboratories, Wilmington, USA).
Anti-NGF antibody detection by ELISA
ELISA plates were coated with 0.1 μg/ml muNGF and
blocked with 5% BSA/PBS. muNGF coated wells were
incubated for 1 h at room temperature with recombinant
canine anti-NGF IgG preparations, diluted in PBS/1%
BSA. Antibody concentrations ranging from 40 ng/ml
to 0.625 ng/ml were used to establish a standard curve.
After washing, the plates were incubated with a 1/5000
dilution of rabbit anti-canine IgG-HRP (Sigma, St. Louis,
USA) in PBS/1% BSA. Plates were washed with PBS 0.05%
Tween 20 and developed by the addition of TMB sub-
strate (Thermo Scientific, Waltham, USA). Developmentwas stopped by the addition of 2 M H2SO4 and absorb-
ance read at 450 nm and background was subtracted.
For the detection of NV-01 in canine plasma samples,
the canine plasma was diluted and used in the ELISA
as above. The background for the canine plasma was
determined from the O.D. 450 nm of time zero serum.
Complement C1q binding ELISA
NV-01 cDNA transfected CHO cell supernatants were
concentrated using Vivaspin 20 concentrators (30 kDa
cut-off, Vivaproducts, Littleton, USA). The concentrations
of recombinant antibodies in the CHO cell supernatants
and of purified antibodies were determined by titration
in the anti-NGF ELISA, by comparison with standard
preparations of purified B isotype canine anti-NGF anti-
body (caN-HCB2 + kLC1) or NV-01.
C1q binding was assayed following the method of
Lewis et al. [26]. Plates were coated with 2.5 μg/ml
muNGF and blocked with 5% BSA/PBS. Coated wells
were incubated for 1 h at room temperature with
recombinant canine anti-NGF IgG, diluted in PBS/1%
BSA. Antibody concentrations ranged from 10 μg/ml to
0.5 μg/ml. The plates were washed and incubated for
1 hour at room temperature with human serum or heat
inactivated human serum diluted 1/100 in veronal buffered
saline containing 0.05% Tween-20, 0.1% gelatine and
0.5% BSA. After washing, plates were incubated with a
1/800 dilution of sheep anti-human C1q-HRP (AbD
Serotec, Kidlington, UK) in PBS/1% BSA. After washing,
plates were developed by the addition of TMB substrate
(Thermo Scientific). Development was stopped by the
addition of 2 M H2SO4 and absorbance read at 450 nm.
The O.D. 450 nm obtained using heat-inactivated serum
was used as background and subtracted from the O.D.
450 nm obtained using untreated serum.
Soluble CD64 binding assay to caninised antibodies
The sequence of cDNA encoding canine CD64, the high
affinity Fc receptor gamma R1, was obtained from Ensembl
[www.ensembl.org: ENSCAFT00000018253]. The sequence
was modified as previously used to generate a soluble
human CD64 [27]. The trans-membrane domain was
removed and c-myc and poly-His tags were added to
the C-terminus to allow for detection and purification.
The cDNAs were synthesised, cloned into expression
vectors and protein was expressed by transient trans-
fection of HEK suspension cells (Geneart AG, Life
Technologies, Regensberg, Germany). Soluble canine CD64
(scaCD64) was purified from the HEK cell supernatants
by Ni-Hi Trap chromatography and size exclusion
chromatography (as above).
Microtitre plates were coated with 0.1 μg/ml muNGF
and blocked with 5% BSA/PBS/0.05% Tween-20. Coated
wells were incubated for 1 h at room temperature with
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BSA/0.05% Tween-20. Antibody concentrations ranged
from 100 ng/ml to 1.6 ng/ml. After washing, plates were
incubated with 1 μg/ml purified scaCD64. Plates were
washed and binding of scaCD64 detected by the addition
of anti-c-myc-HRP (Pierce) in PBS/1% BSA/0.05% Tween-
20. After washing plates were developed by the addition
of TMB substrate (Thermo Scientific). Development was
stopped by the addition of 2 M H2SO4 and absorbance
read at 450 nm. The background (no canine IgG) was
subtracted.
Antibody binding kinetics
The binding affinity of NV-01 to muNGF was analysed
by Surface Plasmon Resonance (SPR) using a ProteOn
XPR36 SPRi biosensor equipped with a GLM chip
(BioRad, Hercules, USA). The chip was conditioned
with 0.5% SDS, 50 mM NaOH and 100 mM HCl. Fol-
lowing conditioning, the lanes were activated using
equal parts of EDAC and NHS amine coupling reagents
(BioRad). The NGF protein was immobilised to the
chip at a concentration of 50 μg/mL in sodium acetate
buffer (pH 4.5). Following immobilisation all three
channels were deactivated using ethanolamine. NV-01
was passed across the surface at 500 nM, 250 nM, 125
nM, 62.5 nM and 31.25 nM. The binding was displayed
as a spectrogram. Controls were subtracted to give specific
binding. A Langmuir curve fit model was then used to
determine the specific affinity.
TF-1 proliferation-inhibition assay
TF-1 cells were maintained in RPMI 1640 medium,
supplemented with 10% foetal calf serum, 10 mM HEPES,
penicillin/streptomycin (10 U/ml and 100 ug/ml final
respectively) and 2 ng/ml GM-CSF. The TF-1 cells
were centrifuged and resuspended in "starve media" (as
above with no GM-CSF). The flasks were incubated in
a humidified 37°C, 5% CO2 incubator for 24 hours. For
the assay, 1x105 GM-CSF starved cells were used per
well. Half-maximal proliferation of TF-1 cells was
observed at 1 ng/mL muNGF and dilutions of NV-01
(2.5 ng/ml to 0.002 ng/ml) were titrated against this
concentration of NGF. The plates were incubated for
48 hours at 37°C/5% CO2 prior to measuring proliferation
CellTiter 96 Aqueous One Solution Cell Proliferation
Assay, Promega, Madison, USA). The assay was performed
in triplicate. A mouse IgG2a mAb (eBM2a, eBioscience,
San Diego, USA) was used as a negative control.
Model of inflammatory pain
A model of inflammatory pain in the cat, induced by
injection of kaolin into the footpad [28], was adapted
for use in the dog ([29], following institutional ethics
review; at Charles River Laboratories (CRL), Ballina,Ireland). Following kaolin injection into the footpad,
the dog becomes lame in that leg within 24 h and then
progressively recovers over a period of 7–14 days and
is then returned to the colony. Following review and
approval by the CRL institutional ethics committee (ref
AUS001\12-003), the kaolin model was used to assess
the potential for NV-01 delivered by intravenous (i.v.)
or sub-cutaneous (s.c.) routes as a pain-relieving drug
in the dog. The study was positively controlled using oral
meloxicam, given as a single loading dose (0.2 mg/kg)
24 h post-kaolin, followed by six daily maintenance
doses of 0.1 mg/kg. Vehicle (PBS) was administered i.v.
as a negative control on day 0. All dogs were prepared
for i.v. administration to maintain blinding during the
observation period. NV-01 was given once as a single
i.v. or s.c. dose of 0.2 mg/kg. This dose was selected
based on the human anti-NGF antibody tanezumab as
used in human clinical trials [11]. To maintain blinding,
the administration of the test articles were performed
by investigators separate to those who assessed lameness.
The investigators involved in the lameness assessments
were masked to the treatments administered in order to
reduce bias due to subjectivity. The investigators involved
in the administration of NV-01, meloxicam or vehicle
control were not masked.
Thirty-two dogs (17 male and 15 female) were enrolled
in the study and randomly allocated to four treatment
groups (n = 8 per group). Animals assigned to Group 1
served as a negative control group and were treated with
PBS administered by i.v. infusion. Animals assigned to
Group 2 were treated with NV-01 administered by i.v.
infusion at a dose of 0.2 mg/kg once on Study Day 0.
Animals assigned to Group 3 were treated with NV-01
administered by s.c. injection at a dose of 0.2 mg/kg once
on Study Day 0. Animals assigned to Group 4 were treated
with meloxicam, administered daily by oral administration
using the recommended dose of 0.2 mg/kg on Study Day
0 and 0.1 mg/kg daily from Study Day 1 to Study Day 7.
The animals underwent experimental induction of
paw inflammation using kaolin (Sigma). The degree of
lameness induced by kaolin was scored according to 4
levels, where a score of 0 was not lame (full weight
bearing), 1 was slightly lame (not fully weight bearing
but walking well), 2 was moderately lame (slightly weight
bearing and not walking well) and 3 was severely lame
(not weight bearing). All animals that were enrolled in
the study reached the required lameness score (3) 24 hours
after kaolin administration. Endpoint assessments were
performed at the following times: prior to kaolin adminis-
tration, pre-treatment on Study Day 0; and at the following
times after dosing: +0.5 h, +2 h, +4 h, +6 h, +1 d, +2 d, +3
d, +4 d, +5 d, +6 d and +7 d. The lameness scores were
un-blinded and average scores from test article treated
dogs were compared to the placebo control as previously
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a non-parametric Mann–Whitney test (one-tailed).Results
Antibody design and expression in CHO cells
The αD11 antibody [25] binds with high affinity to
mouse and human NGF but binding to canine NGF had
not been previously described. Given the level of sequence
similarity between mouse, human and canine NGF protein
sequences (Figure 1A) we reasoned that αD11-based
caninised antibodies might also bind canine NGF.
A small quantity of canine NGF with a C-terminal poly-
His tag was synthesized in HEK-293 cells and purified
by Ni-HiTrap chromatography. Supernatant of CHO
cells expressing caN-HCB2 + kLC1 (see below) bound
equally well to canine and mouse NGF by ELISA, when
compared to a commercially available mouse anti-NGF
antibody preparation (Figure 2A). The low yield of synthetic
canine NGF precluded its further use and mouse NGF
was used subsequently.
Co-expression in CHO cells of caN-kLC light chain
cDNA with each of the four heavy chain isotype cDNAs
caN-HCA, caN-HCB, caN-HCC and caN-HCD, pro-
duced supernatants containing antibodies “caN-HCA1
+ kLC1”, “caN-HCB2 + kLC1”, “caN-HCC1 + kLC1” andFigure 2 Functional assays of caninised anti-NGF recombinant antibo
anti-NGF antibody to murine (mu) and canine (ca) NGF. CHO cell supernata
a mouse anti-NGF mAb (SC548) and mock transfected CHO cell supernatan
binding to antigen-captured antibodies detected by ELISA. D) High affinity
antibodies detected by ELISA.“caN-HCD2 + kLC1”, respectively that bound to muNGF
equally well by ELISA (Figure 2B).Complement C1q and CD64 binding by recombinant
canine anti-NGF antibodies
Anti-NGF antibody supernatants were used in a com-
plement C1q binding ELISA (Figure 2C). Wells incu-
bated with supernatants containing A and D isotype
heavy chains (caN-HCA + kLC and caN-HCD + kLC)
showed no detectable binding of C1q. By contrast,
C1q bound to wells incubated with supernatants con-
taining B and C isotype heavy chain antibodies (caN-
HCB-kLC and caN-HCC-kLC). These results indicate
that antibodies constructed with canine isotype A and
D type heavy chains are not likely to activate comple-
ment, whereas the B and C type heavy chains are likely
to activate complement.
Each of the canine anti-NGF IgG isotypes was
assayed for their ability to bind to the soluble canine
CD64 (Figure 2D). Type A and D heavy chains (caN-
HCA + kLC and caN-HCD + kLC) showed no binding,
while types B and C (caN-HCB-kLC and caN-HCC-
kLC) both bound the soluble form of CD64. The type
C isotype had a higher level of binding compared to
the type B isotype.dies with different heavy chain (HC) isotypes. A) Binding of canine
nt containing canine anti-NGF B type heavy chain was compared with
t. B) Binding to muNGF determined by ELISA. C) Complement C1q
Fc receptor binding. Soluble canine CD64 binding to antigen-captured
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Analysis by SDS-PAGE (Figure 3A) demonstrated the
predicted heavy and light chain bands under reducing
conditions and the predicted single band (two heavy
chains and two light chains) under non-reducing condi-
tions. A single peak was also observed by size-exclusion
chromatography and this peak was stable to storage
at −20°C and room temperature (~ 25°C) for 3 months
(Figure 3B).
The binding affinity of NV-01 to NGF was assessed
using biosensor assays (Figure 3C). Increasing concen-
trations of NV-01 were passed over immobilized NGF.
After a 60 second binding phase, the flow was switched
to buffer alone, and the near horizontal traces thereafter
indicated a very low off rate. The binding affinity of
NV-01 to NGF was determined to be <1 pM.
The human erythroleukaemic cell line, TF-1, pro-
liferates in response to a number of cytokines inclu-
ding granulocyte-macrophage colony-stimulating factor
(GM-CSF) and nerve growth factor (NGF) [30]. To
determine the IC50 (dose that causes half-maximal
inhibition) of NV-01, 1 ng/ml NGF was incubated with
the NV-01 at concentrations ranging from 2.5 ng/ml to
0.002 ng/ml. The result was an IC50 of 0.02 ng/ml
(Figure 3D).Figure 3 Characterisation of the caninised anti-NGF antibody NV-01.
of NV-01 determined by size-exclusion chromatography following storage
affinity of NV-01 to immobilized NGF. Various concentrations of NV-01 (500
for 60 seconds then the flow switched to buffer. D) Inhibition of NGF indu
NV-01 or an irrelevant IgG control antibody at concentrations ranging fromSafety, pharmacokinetics & immunogenicity of NV-01
in dogs
NV-01 was infused i.v. to 3 dogs at 2 mg/kg and the
dogs were observed for 2 weeks. No adverse events were
observed following infusion: there was no weight change
over the following 14 days, no pyrexia, and standard
clinical chemistry markers were within the standard range
(data not shown).
Plasma samples were taken at various times for subse-
quent pharmacokinetic (PK) analysis of NV-01 concen-
tration using the NGF-binding ELISA. The PK profile
from one dog, representative of the 3 dogs tested, is
shown in Figure 4A. Analysis of the plasma levels of
NV-01 over two weeks following injection demonstrated
a two-phase PK profile typical of antibodies injected to
other mammalian species, with a rapid tissue distribution
(alpha) phase followed by a slower elimination (beta)
phase (Figure 4A). The tissue distribution phase half-life
was approximately12 hours and the elimination phase half-
life was approximately 9 days (range 5–35 days, 95%CI).
Eight months later, two of the dogs were infused i.v. with
a further dose of 2 mg/kg NV-01 and plasma samples
were taken for PK analysis. PK analysis following the
second dose of NV-01 gave a similar profile to that
following the first dose (Figure 4B), indicating thatA) SDS-PAGE of reduced (R) and non-reduced (NR) NV-01. B) Stability
at −20 degrees or room temperature (RT) for 3 months. C) Binding
nM, 250 nM, 125 nM, 62.5 nM and 31.25 nM) were passed over NGF
ced proliferation of TF-1 cells in vitro.1 ng/ml NGF was incubated with
2.5 ng/ml to 0.002 ng/ml.
Figure 4 Pharmacokinetic profile of NV-01 in the dog. A) Single
dose. NV-01 (2 mg/kg) was infused intravenously and the NV-01
serum concentration assayed by ELISA over a period of 14 days.
B) Repeat dosing in two dogs. NV-01 (2 mg/kg) was administered
by intravenous infusion twice, with a gap of eight months between
each dose. The NV-01 concentration was determined by ELISA in
serum samples taken over a period of 7 days after each infusion.
Figure 5 Efficacy of NV-01 in a model of inflammation induced
pain. A) Average lameness scores are shown for each treatment
group compared with the average lameness scores for the negative
control group: The negative control was a single injection of
phosphate buffered saline by intravenous infusion (IV, black triangles);
Meloxicam (positive control) was given daily per os (PO) (grey squares);
One 0.2 mg/kg dose of NV-01 was given by intravenous infusion (blue
triangles); or one 0.2 mg/kg dose of NV-01 was given by subcutaneous
injection (SC) (green circles). Points are the mean of eight animals per
group. Error bars are the standard error of the mean. * p < 0.10; ** p <
0.05; *** p < 0.01 (Mann–Whitney test, one-tailed: test article compared
to placebo). Arrows represent administration of the test article on the
specified day. B) NV-01 serum concentration was determined by ELISA
over a period of seven days in animals from the study given 0.2 mg/ml
of NV-01 by intravenous infusion (blue triangles) or subcutaneous
injection (green circles). Points are the mean NV-01 serum
concentrations of three animals per group. Error bars are the
standard deviation.
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immunogenic response.
Comparison of the efficacy of NV-01 and meloxicam in a
model of inflammatory lameness in the dog
Kaolin injection to the footpad of dogs resulted in a
consistent inflammatory lameness score of 3 (severely
lame, not weight bearing) 24 hours later. Four groups
of dogs were then treated with PBS placebo, oral
meloxicam, i.v. NV-01 or s.c. NV-01. Lameness scores
determined by assessors blinded to the type of intervention
were determined on a four-point scale. Following 7 days
of observations, the lameness scores were un-blinded,
averaged according to intervention type and compared
with placebo (i.v. PBS infusion). Figure 5A shows lameness
scores for meloxicam-treated or NV-01-treated dogs
compared with PBS-treated dogs.
Following the initial lameness caused by kaolin injec-
tion, the control PBS-injected dogs remained fully lame
for another day, and then slowly but progressivelyimproved over the following week (PBS IV, Figure 5A).
As anticipated, daily oral meloxicam was effective in
reducing lameness compared with i.v. PBS. The effect
of daily oral meloxicam in reducing average lameness
scores was matched by the single i.v. dose of NV-01:
with meloxicam, significant difference (Mann–Whitney
test: p ≤ 0.10) to placebo was observed at 6 h and on
Day 1, 5, 6 and 7; whereas with i.v. NV-01, significance
compared with placebo was seen on Day 1, 3, 6 and 7.
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compared to placebo later with significance at Day 7.
PK analysis of plasma NV-01 levels (Figure 5B) from
the dogs treated with i.v. or s.c. NV-01 showed a
delayed rise in circulating NV-01 following s.c. injection
compared with i.v. infusion and that the circulating
NV-01 levels were approximately equal 5–7 days
following administration.
Discussion
Methods for the conversion of antibodies from rodent to
human are well described and are routinely used for the
production of humanised antibodies for clinical use. For
example CDR grafting [31,32] makes use of germline
antibody framework sequence as donor sequence for
primary antibody construction. This method often pro-
duces antibodies of lower affinity for antigen than the
donor antibody. Affinity restoration or "maturation" is
achieved by replacement of donor framework residues
until affinity is restored but this often results in antibodies
that are incompletely converted and so potentially
more immunogenic. Rather than use germline donor
sequences, we devised a simpler but more effective
method (termed PETisation) using expressed cDNA
sequences of the desired target species, in this case, the
dog. Analysis of the greater range of framework sequence
possibilities in canine IgG heavy and light chains enabled
substitution of fewer (22 heavy chain) residues of the
donor antibody to covert to a fully canine antibody
framework than had we started with germline sequence
(35 heavy chain). By making fewer changes, the resulting
antibody is structurally most similar to the starting
antibody and yet fully caninised. The advantages of this
simple approach are: 1) the minimum changes are required
to yield an antibody that has considerable similarity to
the starting antibody, 2) the changes made are on the
surface of the antibody structure and so do not affect
the immunoglobulin fold and CDR presentation, and 3)
the resulting antibody is completely caninised and so
can be expected to be non-immunogenic.
The anti-NGF antibody αD11 is well described [7,25]
and was considered a good candidate for conversion
for use in dogs based on its high affinity to mouse and
human NGF and its activity both in vitro and in vivo
[7]. Although sequence differences between murine,
human and canine NGF had the potential to affect
αD11 binding, they were few and distant to the epitope
[33]. Our results with NV-01 indicate that it retained
the high affinity and activity of the αD11 antibody
in vitro and was expressed at high levels in CHO cells
and was stable following prolonged incubation at room
temperature.
NGF is expressed on nerves and is subject to retro-
grade transport. The safe use of anti-NGF antibodiesdemands that the antibody not recruit effector functions
of the immune system, such as complement-dependent
cytotoxicity, and so avoid nerve damage. By direct
analogy, anti-NGF antibodies for human use have been
constructed from effector negative isotypes. The effector
functions of canine antibodies were not previously
described and so we expressed the caninised antibodies
with each of the four canine isotypes previously described
[21]. Two of the isotypes (IgG-heavy chain A and D)
did not bind complement C1q (the first component of
the complement cascade) and so were chosen for further
development for their improved safety profile. Interest-
ingly, neither antibody isotype bound to the high affinity
FcR CD64 (a macrophage receptor involved in the pro-
cesses of opsonisation and the respiratory burst), nor to
Protein A or Protein G.
Anti-NGF mAb therapies are particularly attractive be-
cause of their potential to provide long-lasting analgesia
in chronic disease settings, such as osteoarthritis and
cancer pain. As a prelude to testing the potential of
neutralising NGF in the management of pain in chronic
canine diseases, a kaolin model of short -term inflammatory
lameness was chosen to evaluate the efficacy of NV-01
in dogs in vivo. The kaolin model, first validated in cats
and then in dogs, has the advantage that the animals
recover quickly over the period of about 7–14 days and
are returned to the colony. However, this ethical advantage
also limits the model since there is not a stable period
of inflammation during which direct comparisons can
be made between drug and placebo [29]. Consequently,
any drug benefit must be compared against a steady
improvement in limb function in the placebo treated
dogs. Presently, there are no ethically equivalent models of
long-term inflammation in dogs and so the kaolin model
was deemed most appropriate for this initial assessment
of the potential pain-relieving properties of NV-01.
In the canine kaolin model, oral meloxicam therapy
was effective at reducing signs of lameness in the first
hours after treatment, whereas intravenously infused
NV-01 required longer to become effective presumably
due to slower distribution from the blood to inflamed
tissue of the larger antibody molecule (Figure 5). Following
this distribution phase, the single i.v. dose of NV-01
was similarly effective as daily oral meloxicam at reducing
lameness. Sub-cutaneously delivered NV-01 was also
shown to be active in reducing lameness, but somewhat
later than following i.v. delivery due to the slower redistri-
bution from skin to blood and then to inflamed tissue
following the s.c. route of administration. Nonetheless,
these studies confirm that both i.v. and s.c. routes of
administration of NV-01 have potential to provide pain
relief in dogs. As with studies of anti-NGF in the mouse
[8], neither rectal temperature, nor paw circumference
was affected by meloxicam or NV-01 therapies.
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long half-lives and are more suited to treatment of
chronic diseases. Pharmacokinetic analyses showed
that following i.v. infusion, NV-01 has an approxi-
mately 9-day half-life and has the potential to be adminis-
tered repeatedly to dogs without inducing a neutralising
immune response. The slow rate of decline shown in the
pharmacokinetic analysis in Figure 4A suggests that a
single injection may confer an extended period of thera-
peutic benefit in the treatment of chronic pain. This
combination of safety, long half-life and low immuno-
genicity suggests that NV-01 should be further evaluated
as a therapy for chronic pain conditions in dogs, where
a safety profile superior to current therapies together with
a long duration between injections would be clinically
desirable attributes for a novel therapeutic agent.
Conclusion
These preliminary studies lead us to conclude that the
novel fully caninised anti-NGF mAb NV-01 shows consi-
derable potential as an analgesic for dogs.
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